Combination Immunotherapies in Patients Who Previously Received Immune Checkpoint Inhibitors (QUILT-3.055)
Clinicaltrials.gov identifier:
NCT03228667
Treatment
Study Contact Information:
For additional information, please contact:
Jayson Garmizo by phone: 310-912-2230 or by email or
Brooke Greenley by phone: 919-810-0367 or by email.
A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment with Immune Checkpoint Inhibitors (QUILT-3.055)
About the Study
Immune checkpoint inhibitors are drugs that allow the immune system to find and destroy cancer cells.
This study will use a combination of immunotherapies in people who's cancer got worse after treatment with a PD-1 or immune checkpoint inhibitor. NOTE: This study is no longer recruiting.
Type of Study
This is an study. All participants will receive study drugs and all will know which medications they are receiving. Participants will be assigned to one of five groups based on cancer type and response to prior treatment.
What the Study Entails
All patients in Groups 1-4 will receive treatment with an immune checkpoint inhibitor plus the novel agent N-803 for up to 17 cycles, where each cycle is six weeks in duration.
Some patients in Groups 1-4 whose cancer grows while on study may roll over into Group 5. Group 5 participants will receive treatment with an immune checkpoint inhibitor, the new agents N-803 and t-haNK cellular therapy for up to an additional 17 cycles, where each cycle is six weeks in duration.
Radiologic evaluation will occur at the end of each treatment cycle.
Treatment will continue for up to 2 years, or until the patient experiences progressive disease or an keeps the participant from continuing in the study.
NOTE: This study is no longer recruiting.